Daniel Erez1, Feda Fanadka2, Sydney Benchetrit3,4, Keren Cohen-Hagai3,4. 1. Department of Internal Medicine D, Meir Medical Center, Kfar Saba, Israel. 2. Department of Radiology, Meir Medical Center, Kfar Saba, Israel. 3. Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel. 4. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
INTRODUCTION: The prevalence of intracranial arterial calcification (ICAC) in maintenance hemodialysis (MHD) patients is about 90%, and its severity is correlated with age, hemodialysis vintage, and mineral bone disease. Elevated concentrations of calcium and phosphorus are not sufficient for medial calcification because of inhibition by pyrophosphate. Alkaline phosphatase (ALP) promotes calcification by hydrolyzing extracellular pyrophosphate. Epigenetic mechanisms involving ALP inhibition by apabetalone were investigated as a potential target for preventing vascular calcifications (VCs). This study assessed the combined impact of VCs and elevated serum ALP on mortality among chronic HD patients. METHODS: VCs represented by ICAC were measured simultaneously with mineral bone disease parameters including serum ALP of MHD patients who underwent noncontrast brain computed tomography from 2015 to 2018 in our institution. RESULTS: This retrospective study included 150 MHD patients (mean age 71.3 ± 12.1 years, 60.1% male). Of the total cohort, 12 (7.8%) had no brain calcifications and 69 (45.1%) had multiple intracranial calcifications. Considering the patients with normal ALP and no calcification as the reference group yielded adjusted odds ratios for all-cause mortality of 4.6 (95% CI: 1.7-12.7) among patients with brain calcifications and normal ALP (p = 0.003) and odds ratios for all-cause mortality of 6.1 (95% CI: 2.1-17.7) among patients with brain calcifications and elevated ALP (p= 0.001). CONCLUSION: We found an independent association between ICAC and the risk of death among MHD patients. The combined effect of ICAC and elevated ALP was associated with a higher odds ratio for all-cause mortality in MHD patients and may contribute to the risk stratification of these patients. The Author(s). Published by S. Karger AG, Basel.
INTRODUCTION: The prevalence of intracranial arterial calcification (ICAC) in maintenance hemodialysis (MHD) patients is about 90%, and its severity is correlated with age, hemodialysis vintage, and mineral bone disease. Elevated concentrations of calcium and phosphorus are not sufficient for medial calcification because of inhibition by pyrophosphate. Alkaline phosphatase (ALP) promotes calcification by hydrolyzing extracellular pyrophosphate. Epigenetic mechanisms involving ALP inhibition by apabetalone were investigated as a potential target for preventing vascular calcifications (VCs). This study assessed the combined impact of VCs and elevated serum ALP on mortality among chronic HD patients. METHODS: VCs represented by ICAC were measured simultaneously with mineral bone disease parameters including serum ALP of MHD patients who underwent noncontrast brain computed tomography from 2015 to 2018 in our institution. RESULTS: This retrospective study included 150 MHD patients (mean age 71.3 ± 12.1 years, 60.1% male). Of the total cohort, 12 (7.8%) had no brain calcifications and 69 (45.1%) had multiple intracranial calcifications. Considering the patients with normal ALP and no calcification as the reference group yielded adjusted odds ratios for all-cause mortality of 4.6 (95% CI: 1.7-12.7) among patients with brain calcifications and normal ALP (p = 0.003) and odds ratios for all-cause mortality of 6.1 (95% CI: 2.1-17.7) among patients with brain calcifications and elevated ALP (p= 0.001). CONCLUSION: We found an independent association between ICAC and the risk of death among MHD patients. The combined effect of ICAC and elevated ALP was associated with a higher odds ratio for all-cause mortality in MHD patients and may contribute to the risk stratification of these patients. The Author(s). Published by S. Karger AG, Basel.
Entities:
Keywords:
Alkaline phosphatase; Hemodialysis; Mineral bone disease; Vascular calcifications
Authors: Sarah Picaud; Christopher Wells; Ildiko Felletar; Deborah Brotherton; Sarah Martin; Pavel Savitsky; Beatriz Diez-Dacal; Martin Philpott; Chas Bountra; Hannah Lingard; Oleg Fedorov; Susanne Müller; Paul E Brennan; Stefan Knapp; Panagis Filippakopoulos Journal: Proc Natl Acad Sci U S A Date: 2013-11-18 Impact factor: 11.205
Authors: Jason P Linefsky; Kevin D O'Brien; Ronit Katz; Ian H de Boer; Eddy Barasch; Nancy S Jenny; David S Siscovick; Bryan Kestenbaum Journal: J Am Coll Cardiol Date: 2011-07-12 Impact factor: 24.094
Authors: Mathias Haarhaus; Kausik K Ray; Stephen J Nicholls; Gregory G Schwartz; Ewelina Kulikowski; Jan O Johansson; Michael Sweeney; Christopher Halliday; Kenneth Lebioda; Norman Wong; Vincent Brandenburg; Srinivasan Beddhu; Marcello Tonelli; Carmine Zoccali; Kamyar Kalantar-Zadeh Journal: Atherosclerosis Date: 2019-09-17 Impact factor: 5.162
Authors: Dean Gilham; Laura M Tsujikawa; Christopher D Sarsons; Christopher Halliday; Sylwia Wasiak; Stephanie C Stotz; Ravi Jahagirdar; Michael Sweeney; Jan O Johansson; Norman C W Wong; Kamyar Kalantar-Zadeh; Ewelina Kulikowski Journal: Atherosclerosis Date: 2018-11-14 Impact factor: 5.162
Authors: Robert N Foley; Anne M Murray; Shuling Li; Charles A Herzog; A Marshall McBean; Paul W Eggers; Allan J Collins Journal: J Am Soc Nephrol Date: 2004-12-08 Impact factor: 10.121
Authors: Deborah L Regidor; Csaba P Kovesdy; Rajnish Mehrotra; Mehdi Rambod; Jennie Jing; Charles J McAllister; David Van Wyck; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: J Am Soc Nephrol Date: 2008-07-30 Impact factor: 10.121